Cite
MLA Citation
L. Wang et al.. “131P First-line HDACi plus tislelizumab combined with chemotherapy in advanced NSCLC.” Immuno-oncology technology, vol. 16, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100172111635.0x000007
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
L. Wang et al.. “131P First-line HDACi plus tislelizumab combined with chemotherapy in advanced NSCLC.” Immuno-oncology technology, vol. 16, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100172111635.0x000007